Morgan Stanley initiated coverage of Zealand Pharma (ZLDPF) with an Equal Weight rating and DKK 755 price target The company’s next major catalyst is a petrelintide partnership, but there is limited visibility on the timing and terms, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF: